Close menu

December 10th, 2021 | 12:54 CET

Daimler, Daimler Trucks, Ayurcann, TUI: Great yield gifts in the Advent season!

  • Cannabis
Photo credits:

The so-called quiet time before Christmas is often associated with cozy warmth, gingerbread and mulled wine. At the stock exchange, the books of the large investors close and private investors optimize their capital gains tax by the realization of pending losses. Because from a pure tax point of view, losses from private sales transactions can be set off against profits; only the annual residual profit then has to be taxed. As a result, the autumn stock markets are often more stormy than many people think, and there is less of a sense of "quiet time," according to Christian beliefs. We pick out a few pieces of gingerbread!

time to read: 4 minutes | Author: André Will-Laudien
ISIN: DAIMLER AG NA O.N. | DE0007100000 , Daimler Truck Holding AG | DE000DTR0013 , AYURCANN HOLDINGS CORP | CA05476A1012 , TUI AG NA O.N. | DE000TUAG000

Table of contents:

    Daimler AG - Daimler Trucks goes public today

    The stock market waited a long time for the big event at Daimler AG. Daimler's truck division is now an independent company after the spin-off and the entry into the commercial register. As the physical spin-off in a ratio of 2:1 should have been technically completed overnight, Daimler Truck AG can be listed for the first time today.

    At a capital markets day in the fall, the commercial vehicle manufacturer reiterated its goal of a group-wide double-digit return by 2025 under good market conditions and broke down the figures for the individual regions. For the US and Canada, the most profitable markets, the Company is aiming for an adjusted return on sales of 12%, Mercedes-Benz Trucks in Europe 10% and Truck Asia 9%. Most recently, Trucks in Europe had the lowest margin of the three regions at 4.5%; for the pandemic-hit bus business, the target is 7.5%. In Germany, the Company competes directly with VW subsidiary Traton, which combines MAN and Scania.

    In the Daimler Group, passenger cars and trucks & buses will be separated in the future. After the truck IPO, the remaining Daimler AG will be renamed Mercedes-Benz Group AG in February. Don't be alarmed; today, a DAX test run with a temporary 41 values ​​enables index ETFs to readjust their weightings.

    Daimler shares did splendidly in the run-up to the split. It is one of the DAX winners of 2021, with a share price performance of 49% plus a dividend of EUR 2.34. A nice St. Nicholas present for shareholders; the appreciation should continue after the split.

    Ayurcann - Good crop results in the last 3 months

    We switch segments now from the cutting-edge automotive industry to the diversified cannabis industry. There we meet Ayurcann Holdings Corp., a leading provider of so-called post-harvest solutions. The Company specializes in the provision and development of customized processes, focusing on pharmaceutical and beneficial products made from the hemp plant for adults. Ayurcann is also a specialist in medical preparations and primarily addresses B2B customers.

    Ayurcann is counting on the gradual opening of markets, some of which are heavily regulated, and sees definite opportunities for the political climate in Europe to prevail in favor of hemp healing approaches. With the plans of the new traffic light coalition, the chances are also not bad in Brussels for a general release of the hemp plant under certain quality and due diligence obligations.

    Figures for the last 9 months have now been released. Ayurcann achieved net sales of USD 1.9 million, an increase of 137% YOY. Gross profit developed from USD 169,000 to USD 931,000, a good fivefold increase with a 49% margin. Ayurcann completed the Phase 2 expansion of its new Pickering facility, increasing extraction capacity to 300,000 kg of input biomass and up to 3 million filling and co-packing capacity for cannabis products. The Company's extraction service provides a go-to-market strategy for licensed producers from Canada. Inventory increased to approximately 300 kg of raw THC (tetrahydrocannabinol) and CBD (cannabidiol) distillate and isolate in pharmaceutical-grade for use in Cannabis 2.0 and 3.0 products available for its co-manufacturing and white label partnerships.

    Ayurcann Holdings is expanding into various recreational markets and is currently shipping its cannabis 2.0 products across Canada. Key products include Fuego brand vapes and Vida brand tinctures shipped to New Brunswick and Saskatchewan. Additional orders will be placed to Manitoba, Ontario and Alberta in the coming quarters, with contracts already made. Ayurcann is currently proving a solid beat, but the stock is still relatively undiscovered with a valuation of around CAD 16 million. One should put a few pieces under the Christmas tree because the AYUR share is not expensive and is operationally profitable for several quarters already compared to many established companies.

    TUI - This could be the hit for 2022

    It is not just vacationers who are thinking about next year's travel options. At TUI AG, there have been historic changes in the group's lineup over the past 2 years. Most recently, for example, the previously independent airlines have been brought together under one roof. Online bookings were dramatically increased, and significant savings have been made in the distribution area. Today, TUI is no longer primarily dependent on the travel agency business, and the Company has digitized itself and become more weatherproof.

    Nevertheless, high debt and a low equity ratio are depressing the mood. The second Corona year has brought another billion-dollar loss for the world's largest travel group. Thanks to recent strong booking figures, however, CEO Fritz Joussen ventured an optimistic forecast when presenting the 2021 annual financial statements: "We expect a return to a booking level for summer 2022 and the peak travel season roughly like before Corona 2019."

    Overall, however, the manager did not rule out another capital increase, as TUI could need the money to repay billions in state aid. The Hanover-based company raised only EUR 1.1 billion in the fall with another capital increase. Revenue plunged by around 40% to EUR 4.7 billion in 2021, after the winter half-year 2019/2020 had hardly been affected by Corona. The bottom line was now a shortfall of almost EUR 2.5 billion - still a good fifth less than a year earlier. On December 6, the TUI Group had cash and cash equivalents and credit lines of EUR 3.5 billion. Overall, TUI counted only 5.4 million guests in the past financial year, of which 3.8 million were in the summer quarter. That means business from July to September was only around 50% of the pre-crisis level.

    If these figures are anything to go by, TUI can only keep its fingers crossed that sensible pandemic regulations will make travel possible again. As we all know, you can catch an infection anywhere, so why ban the much-needed days of relaxation in the year? From this point of view, TUI could be the best seller in 2022. Collect cautiously at EUR 2.60 and let it lie.

    The stock market in 2021 is slowly closing its doors. Some tax peculiarities lead to special movements when prices fall sharply. These can be used. Daimler lets its investors participate in a split, Ayurcann and TUI entice with a low valuation.

    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.

    Der Autor

    André Will-Laudien

    Born in Munich, he first studied economics and graduated in business administration at the Ludwig-Maximilians-University in 1995. As he was involved with the stock market at a very early stage, he now has more than 30 years of experience in the capital markets.

    About the author

    Related comments:

    Commented by Fabian Lorenz on February 14th, 2023 | 15:46 CET

    Biotech stocks on the verge of a breakout? Evotec, BioNTech, Cardiol Therapeutics

    • Biotechnology
    • Cannabis
    • Cancer

    Biotech stocks have largely missed out on the rally of recent weeks. But this could change. Some have interesting chart constellations or a positive news flow. Sooner or later, the stock should then also react with a breakout. After the horror year 2022, Evotec received several positive reports within a few days. The share price has also jumped. At BioNTech, investors are looking away from the COVID-19 vaccine and towards the development pipeline. But, analysts disagree. Are 100% share price gains on the cards? Analysts believe that Cardiol Therapeutics' stock has even more potential than that. Its main product against heart inflammation is already in the Phase II pilot study, and the necessary capital for further development is available. All three shares are recommended as a buy by analysts.


    Commented by Armin Schulz on February 8th, 2023 | 11:49 CET

    BioNTech, Pfizer, Cardiol Therapeutics, Bayer - Biotech stocks facing a revival?

    • Biotechnology
    • Cancer
    • vaccine
    • Cannabis

    The BIO Deutschland association represents the German biotech industry. According to an announcement on January 18, financing of biotech companies plummeted by 2/3 in 2022. Overall, the sector raised only EUR 920 million in equity. During the Corona pandemic, many biotech stocks did well. Subsequently, profit-taking occurred and rising interest rates put additional pressure on stocks. That could change in 2023. Meanwhile, some companies are valued low, and so these companies appear on the radar of investors from the United States. According to Handelsblatt, Water Street, an investment company focused on pharma and biotech, has already invested EUR 1 billion, mainly in Germany. A total of EUR 6 billion is to be invested.


    Commented by Nico Popp on February 2nd, 2023 | 18:04 CET

    Bulging pipeline at BioNTech, Cardiol Therapeutics - what is the problem at Aurora Cannabis?

    • Biotechnology
    • Cannabis
    • Cancer

    He who heals is right. It is not quite that simple with active ingredients that are about to be approved. Drugs and vaccines must undergo extensive studies and, last but not least, have to prevail against the existing competition. We look at the pipelines of three hot stocks and venture a forecast: Where is the greatest potential for investors?